Floatz logo

Atirmociclib

PIK3CA Mutation

Relay Therapeutics, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the PIK3CA Mutation cohort.

Asset / SponsorPhaseRating
Benzamide, N-[(3R)-3-(2-chloro-5-fluorophenyl)-6-(5-cyano[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,3-dihydro-1-oxo-1H-isoindol-4-yl]-3-fluoro-5-(trifluoromethyl)-
Relay Therapeutics, Inc.
Phase 3BB
FULVESTRANT
Relay Therapeutics, Inc.
Phase 3B
Capivasertib
Relay Therapeutics, Inc.
Phase 3B
Abemaciclib
Relay Therapeutics, Inc.
Phase 1CC
Zoladex
Relay Therapeutics, Inc.
Phase 1CC

View all 16 →

Same molecule, other indications

Atirmociclib is also rated in:

breast cancerDormant
B
Indicative ·
63 / 100
View asset →
breast cancerDormant
B
Indicative ·
59 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →